HTG Molecular Diagnostics (HTGM) Launches Next-Gen Assay for Diffuse Large B-Cell Lymphomas

HTG Molecular Diagnostics, Inc,, a provider of instruments and reagents for molecular profiling applications, announced the availability of the HTG EdgeSeq Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin Assay (research use only). DLBCL, the most common form of non-Hodgkin’s lymphoma (NHL) in adults, is characterized by two major subtypes, activated B-cell-like (ABC) and germinal center B-cell-like (GCB). The HTG EdgeSeq DLBCL Cell of Origin Assay classifies DLBCL as ABC or GCB and was trained and validated on over 250 cases previously subtyped through microarray-based gene expression profiling. Automated on the HTG EdgeSeq system, the assay couples HTG’s proprietary nuclease protection chemistry with next-generation sequencing (NGS).

HTG Molecular Diagnostics (HTGM) Launches Next-Gen Assay for Diffuse Large B-Cell Lymphomas
Street Insider